Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Meca-Lallana J, Ayuso T, Martínez-Yelamos S, Durán C, Contreras Martín Y, Herrera Navarro N, Pérez Sempere A, Álvarez-Cermeño JC, Millán Pascual J, Meca-Lallana V, Romero Sevilla R, Ricart J. Meca-Lallana J, et al. Eur Neurol. 2020;83(1):25-33. doi: 10.1159/000505778. Epub 2020 Mar 18. Eur Neurol. 2020. PMID: 32187609 Free PMC article.
Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain.
Aladro Y, Terrero R, Cerezo M, Ginestal R, Ayuso L, Meca-Lallana V, Millán J, Borrego L, Martinez-Ginés M, Rubio L, de Andrés C, Miralles A, Guijarro C, Rodríguez-García E, García-Dominguez JM, Muñoz-Fernández C, López de Silanes C, Gómez M, Thuissard I, Cerdán M, Palmí I, Díaz-Garzón LF, Meca-Lallana J. Aladro Y, et al. J Neurol Sci. 2016 Jun 15;365:16-21. doi: 10.1016/j.jns.2016.03.050. Epub 2016 Apr 2. J Neurol Sci. 2016. PMID: 27206867
[Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J, Meca-Lallana V, Barrero F, Martinez-Gines ML, Marzo-Sola ME, Ricart J, Garcia E, En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN. Mallada-Frechin J, et al. Rev Neurol. 2018 Sep 1;67(5):157-167. Rev Neurol. 2018. PMID: 30047118 Free article. Spanish.
Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders.
Carreón Guarnizo E, Hernández Clares R, Castillo Triviño T, Meca Lallana V, Arocas Casañ V, Iniesta Martínez F, Olascoaga Urtaza J, Meca Lallana JE. Carreón Guarnizo E, et al. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrl.2018.12.013. Epub 2019 Mar 28. Neurologia (Engl Ed). 2022. PMID: 30928236 Free article. English, Spanish.
Cognitive Dysfunctions and Assessments in Multiple Sclerosis.
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L. Oreja-Guevara C, et al. Front Neurol. 2019 Jun 4;10:581. doi: 10.3389/fneur.2019.00581. eCollection 2019. Front Neurol. 2019. PMID: 31214113 Free PMC article. Review.
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
Barrero F, Mallada-Frechin J, Martínez-Ginés ML, Marzo ME, Meca-Lallana V, Izquierdo G, Ara JR, Oreja-Guevara C, Meca-Lallana J, Forero L, Sánchez-Vera I, Moreno MJ; in representation of the MS NEXT study investigators. Barrero F, et al. PLoS One. 2020 Apr 2;15(4):e0230846. doi: 10.1371/journal.pone.0230846. eCollection 2020. PLoS One. 2020. PMID: 32240213 Free PMC article.
Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
Sabin J, Urtiaga S, Pilo B, Thuissard I, Galan V, Sainz de la Maza S, Costa-Frossard L, Gómez-Moreno M, Díaz-Díaz J, Oreja-Guevara C, Martínez-Ginés ML, Lozano A, Borrega L, Ayuso L, Castro A, Sanchez P, Meca-Lallana V, Muñoz C, Casanova I, López de Silanes C, Martín H, Rodriguez-García E, Moreno I, García-Merino JA, Aladro Y; DMF Study Group. Sabin J, et al. J Neurol. 2020 Aug;267(8):2362-2371. doi: 10.1007/s00415-020-09848-7. Epub 2020 Apr 29. J Neurol. 2020. PMID: 32350647
68 results